Fort Washington Investment Advisors 13F: Cuts CHE Stake by $25M

Fort Washington Investment Advisors reduced its stake in Chemed Corporation (NYSE: CHE) by 49,765 shares, now holding 1,248 shares worth about $630,327, according to the firm’s latest Form 13F filing on October 15, 2026. This cut represents a significant 97.6% decrease in their position.

What Changed in Fort Washington's Chemed Position

Fort Washington’s stake in Chemed Corporation shrank to 1,248 shares after the reduction. The fund's previous holding was 51,013 shares. This sharp decrease indicates a strategic shift within the fund, as they have drastically lowered their investment in this healthcare provider.

Other Institutional Activity in Chemed

Several other funds have also adjusted their positions in Chemed. Blackrock Inc. grew its holdings by 147,573 shares, ending with 1,484,282 shares worth about $760.5 million. AQR Capital Management, LLC increased its stake by 556,869 shares to 972,474 shares valued at approximately $498.3 million. Conversely, Vanguard Portfolio Management LLC reduced its position by 28,631 shares, holding 787,068 shares worth about $403.3 million, and Vanguard Capital Management LLC decreased its holdings by 31,678 shares, now at 604,420 shares valued at approximately $309.7 million. Acadian Asset Management, LLC added 146,353 shares, ending with 453,238 shares worth about $232.2 million.

Chemed Corporation Stock Down 0.8%

Chemed shares recently traded around $511.5, which is below its 50-day moving average of $518.96 but above its 200-day average of $458.40. The stock is about 8.2% lower than its 52-week high of $557.00, indicating a relative weakness, as it has remained above its 52-week low of $365.21 by 40.1%.

Recent Earnings

In its most recent financial report, Chemed Corporation reported trailing twelve-month revenue of $2.6 billion with an EPS of $20.37. The next earnings announcement is expected on October 27, 2026. Chemed's revenue growth year-over-year was 8.8%, and it posted a net margin of 10.6%, showcasing its profitability in the healthcare sector.

Insider Buying and Selling at Chemed Corporation

Recent insider activity included multiple sales by CEO Kevin J. McNamara. He sold 2,000 shares at prices ranging from $501.40 to $539.51 on various dates in September 2026, totaling around $1.0 million in value. Additionally, Director Patrick P. Grace sold 190 shares at $532.00 worth about $101,080 on July 31, 2026. These transactions took place before the latest filing and indicate ongoing adjustments by company insiders.

Analysts Set New Price Targets

On September 25, 2026, UBS initiated coverage on Chemed with a Buy rating and set a price target of $650. Earlier, B of A Securities maintained a Neutral rating with a target of $510. RBC Capital also maintained a Sector Perform rating with a target of $548. Meanwhile, Oppenheimer maintained an Outperform rating with a target of $590.

About Chemed Corporation

Chemed Corporation provides hospice and palliative care services across the United States. It operates primarily through its VITAS segment, which serves patients with terminal illnesses, and the Roto-Rooter segment, which offers plumbing and drain cleaning services. This filing reveals a significant decrease in Fort Washington's position, indicative of a strategic reallocation within their portfolio.

Bottom Line

Investors should watch for Chemed's upcoming earnings report on October 27, 2026, and any further institutional movements. The recent cuts by Fort Washington reflect changing strategies that may continue to evolve in the healthcare sector. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.